Usefulness of Covid-19 patients first analysis made at the Emergency Department as a prediction tool for mortality (PMCovid Score)
e202110144
Keywords:
COVID-19, Coronavirus, Emergency Lab, Score, PrognosticAbstract
Background: The COVID-19 pandemic has generated a high demand for hospital resources taking the national health system to its limit. In order to reduce this over burden and to avoid a potential system collapse, it would be beneficial to generate scientific evidence for the prognosis of the disease and to count with models that are able to forecast the mortality and progression of the disease. Identify mortality risk factors in COVID-19 patients from analytic data obtained from the Emergency Service at our hospital and to elaborate a prognostic score for predicting 30-day mortality (PMCovid Score) that will be included in the report submitted by the Emergency Clinic Laboratory.
Methods: Transversal descriptive study in a population that came to the Emergency Service at the University Hospital of Jaén between March 8th and April 7th 2020. We obtained the variables for the prognosis by a univariate data analysis. On this basis, we applied a multivariate analysis of the logistical regression of the mortality after 30 days in order to generate a prognostic score which was validated subsequently by the TRIPOD method.
Results: 298 patients were included. PMCovid Score assigns 1 point to patients age ≥77 years old; 1 point to patients with a urea level ≥49 mg/dL, 1 point to erythrocyte values <4.6x106/µL, 2 points to platelet values <165x103/µL; 1 point to patients with a percentage of lymphocytes below 18.1%; 1 point to those with a % of monocytes <6.8% and 2 points if the % of eosinophils is <0.4%.Our score had a predictive accuracy of 88.6% (AUC 0.886 IC at 95%; 0.842-0.931), with a sensibility of 91.7% (IC at 95% 82.810-100) and a specificity of 69.7% (IC at 95% 63.840-75.680).
Conclusions: PMCovid Score provides the doctor with information on the prognosis of the positive COVID-19 patient along with the usual first analysis data, the necessary parameters for the calculations are available at all Emergency Laboratory Clinics. This information can be very useful for the management of this kind of patients and their classification based on the risk supplied by the PMCovid Score.
Downloads
References
Wang C et al. A novel coronavirus outbreak of global health concern. Lancet, 2020. 395 (10223): 470-473.
Wu Y et al. SARS-CoV-2 is an appropriate name for the new coronavirus. Lancet, 2020: 949-950.
Du Toit A. Outbreak of a novel coronavirus. Nat Rev Microbiol, 2020. 18(3):123.
World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report–49. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus2019/situation-reports/. Last accessed, March 9, 2020.
European Centre for Disease Prevention and Control. An Agency of the European Union. https://www.ecdc.europa.eu/en/covid-19
Wang C et al. A novel coronavirus outbreak of global health concern. Lancet, 2020. 395 (10223): 470-473.
Wang Y et al. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. J Med Virol. 2020: 1-19
Lippi G et al. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020: 1132-1133.
Wang D et al. Clinical characteristic of 138 hospitalized patients with 2019 novel coronavirus-infected penumonia in Wuhan, China. J Am Med Assoc 2020. 1064.
Frater JL, Zini G, d’Onofrio G, Rogers HJ. Biomarkers and the clinical hematology laboratory. Int J Lab Hematol. 2020 Jun;42 Suppl 1:11-18. doi: 10.1111/ijlh.13229: 11-18.
Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory Markers. Int J Infect Dis. 2020 Jun;95:304-307. doi: 10.1016/j.ijid.2020.04.061. Epub 2020 Apr 25. PMID: 32344011: 304-307.
Ortega Calvo M, Cayuela Domingues A. Regresión logística no condicionada y tamaño de muestra: una revisión bibliográfica. Rev. Esp. Salud Pública vol 76 nº2. Madrid. Mar 2002. ISSN 2173-9110 versión impresa ISSN 1135-5727: 85-93.
Carter JV, Pan J, Rai SN, Galandiuk S. ROC-ing along: Evaluation and interpretation of receiver operating characteristic curves. Surgery. 2016,1638-1645.
Sullivan LM, Massaro JM, D’Agostino RB Sr. Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med 2004;23:1631-1660.
Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P et al. Transparent reporting of a multivariable prediction for individual prognosis and diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med 2015 Jan;162(1):W1-73. Doi: 10.7326/M14-0698: W1-W73.
Informe número 68. Situación de COVID19 en España a 3 de marzo de 2021. https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/INFORMES%20COVID-19%202021/Informe%20COVID-19.%20N%C2%BA68_%2003%20de%20marzo%20de%202021.pdf
Rodriguez-Morales AJ, Cardona-Espina AJ, Gutierrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y et al. Clinical laboratory and imaging features of COVID-19:
a systematic review and meta-analysis. Travel Med Infect Dis. 2020: 1-10.
Liu et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020 Mar;63(3):364-374.
Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
García de Guadiana-Romualdo L, Morell-García D, Morales Indiano C, Miquel Bauça J, Alcaide Martín MJ et al. Characteristics and laboratory findings on admission to the emergency department among 2873 hospitalized patients with COVID-19: the impact of adjusted laboratory tests in multicenter studies. A multicenter study in Spain (BIOCOVIDSpain study).Scandinavian Journal of Clinical and Laboratory Investigation. https://doi.org/10.1080/00365513.2021.1881997: 1-7.
Sepulchre E, Pittie G, Stojkovic V, Haesbroek G, Crama Y et al. Covid-19: contribution of clinical characteristics and laboratory features for early detection of patients with risk of severe evolution. Acta Clinica Belgica. https://doi.org/10.1080.17843286.2020.1822078: 1-7.
Xiang J, Wen J, Yuan X, Xiong S, Zhou X, Liu C et al. Potencial biochemical markers to identify severe cases among COVID-19 patients. MedRxiv 2020.03.19.20034447; DOI: 10.1101/2020.03.19.20034447: 1-10.
Maguire D, Woods M, Richards C, Dolan R, Wilson Veitch J et al. Prognostic factors in patients admitted to an urban teaching hospital with COVID-19 infection. J Transl Med (2020) 18:354 https://doi.org/10.1186/s12967-020-02524-4: 2-10.
Ji D, Zhang D, Xu J et al. Prediction for progression risk in patients with COVID-19 pneumonia: The CALL Score: 1393-1399.
Francone M, Lafrate F, Masci GM et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis: 6808-6817.
Pascual Gómez NF, Monge Lobo I, Granero Cremades I, Figuerola Tejerina A, Ramasco Rueda F et al. Potenciales biomarcadores predictores de mortalidad en pacientes COVID-19 en el Servicio de Urgencias. Revista española de quimoterapia. DOI: 10.37201/req/060.2020:0: 267-273.
Vultaggio A, Vivarelli E, Virgili G, Lucenteforte E, Bartoloni et al. Prompt predicting of early clinical deterioration of moderate to severe COVID-19 patients: usefulness of a combined Score using IL-6 in a preliminary study. American Academy of Allergy, Asthma & Immunology. https://doi.org/10.1016/j.jaip.2020.06.013: 1-9.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Ana Belén García-Ruano, Soledad García-Chileme, Alba Martínez-Chamorro, Esther Martínez-Lara, Ramón Coca-Zúñiga
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
